about
Spatiotemporal controlled delivery of nanoparticles to injured vasculatureAdministration routes and delivery systems of bisphosphonates for the treatment of bone resorption.Technical advance: liposomal alendronate depletes monocytes and macrophages in the nonhuman primate model of human diseaseReduced cytotoxicity and enhanced bioactivity of cationic antimicrobial peptides liposomes in cell cultures and 3D epidermis model against HSV.Physicochemical parameters affecting liposomal bisphosphonates bioactivity for restenosis therapy: internalization, cell inhibition, activation of cytokines and complement, and mechanism of cell death.Liposomal simvastatin attenuates neointimal hyperplasia in rats.Single and double emulsion manufacturing techniques of an amphiphilic drug in PLGA nanoparticles: formulations of mithramycin and bioactivity.Nanosuspensions of alendronate with gallium or gadolinium attenuate neointimal hyperplasia in rats.Alendronate-loaded nanoparticles deplete monocytes and attenuate restenosis.Systemic depletion of macrophages by liposomal bisphosphonates reduces neointimal formation following balloon-injury in the rat carotid artery.Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit.Synthesis and preclinical pharmacology of 2-(2-aminopyrimidinio) ethylidene-1,1-bisphosphonic acid betaine (ISA-13-1)-a novel bisphosphonate.In vitro and in vivo effects of tetrakisphosphonates on bone resorption, tumor osteolysis, ectopic calcification, and macrophages.Prevention of bioprosthetic heart valve tissue calcification by charge modification: effects of protamine binding by formaldehyde.Route of administration-dependent anti-inflammatory effect of liposomal alendronate.Mode of administration-dependent pharmacokinetics of bisphosphonates and bioavailability determination.Site-specific delivery of dexamethasone from biodegradable implants reduces formation of pericardial adhesions in rabbits.Macrophage depletion by clodronate-containing liposomes reduces neointimal formation after balloon injury in rats and rabbits.Tyrphostin AGL-2043 eluting stent reduces neointima formation in porcine coronary arteries.Novel PDGFbetaR antisense encapsulated in polymeric nanospheres for the treatment of restenosis.Controlled periadventitial administration of verapamil inhibits neointimal smooth muscle cell proliferation and ameliorates vasomotor abnormalities in experimental vein bypass grafts.Monocyte-mediated drug delivery systems for the treatment of cardiovascular diseases.Peritoneal macrophage depletion by liposomal bisphosphonate attenuates endometriosis in the rat model.Delivery of serotonin to the brain by monocytes following phagocytosis of liposomes.Liposomal temozolomide drug delivery using convection enhanced delivery.Polymeric nanoparticles of siRNA prepared by a double-emulsion solvent-diffusion technique: Physicochemical properties, toxicity, biodistribution and efficacy in a mammary carcinoma mice model.Cardiovascular delivery of drugs and biotherapeutics.The role of monocyte subpopulations in vascular injury following partial and transient depletion.Delivery of Liposomal Quantum Dots via Monocytes for Imaging of Inflamed Tissue.Locally delivered nanoencapsulated tyrphostin (AGL-2043) reduces neointima formation in balloon-injured rat carotid and stented porcine coronary arteries.Number-concentration of nanoparticles in liposomal and polymeric multiparticulate preparations: empirical and calculation methods.Silencing of skeletal metastasis-associated genes impairs migration of breast cancer cells and reduces osteolytic bone lesions.Mechanical properties and histology of charge modified bioprosthetic tissue resistant to calcification.Prevention of bacterial colonization on polyurethane in vitro by incorporated antibacterial agent.Sustained-release local hirulog therapy decreases early thrombosis but not neointimal thickening after arterial stentingPerivascular delivery of heparin for the reduction of smooth muscle cell proliferation after endothelial injuryTargeted siRNA Nanoparticles for Mammary Carcinoma Therapy.Nanoparticulate delivery system of a tyrphostin for the treatment of restenosis.Measurement of serum [3H]tetracycline kinetics and indices of kidney function facilitate study of the activity and toxic effects of bisphosphonates in bone resorptionIn vitro and in vivo anticalcification effects of novel bishydroxyiminophosphonates
P50
Q33529582-2F8B197E-7BCB-4066-A65A-8324C08192B1Q34017621-FD5ABD1B-CF09-4E9C-ABE0-B6FD9CA9979EQ36246121-A1E797E9-E285-4766-A83F-C4CBC28F0688Q38783275-B5ECC59C-1F22-4D12-A817-D9421AA50E79Q39720003-804A8E94-787A-4903-9CB1-4F2BC7295CCFQ39770648-8E8109EB-6BC6-46B0-B60B-AD758CA40F65Q39950357-06E7506A-035D-4270-8A20-3E8EC1F024CFQ40181870-78783E4E-C5E4-4460-BC13-FBBC2DF46683Q40280608-9B96B4AC-2E6C-4700-8640-8E9981C89BD8Q40623402-72531F67-BDEC-4167-BE86-D4217772620FQ40659303-9EB0FAA7-1388-4242-B39D-B64ADF2A3843Q40927404-0C10E94A-B573-4749-A085-C256BEFADAA4Q41125571-10EF6AB5-B844-4C28-8844-E1A80FA74B19Q41162616-54DD71F3-EDE8-40BA-B60C-65D9F8D29725Q42919346-E8FA0B92-3A98-488C-B976-9D2D3B56C899Q43620035-F49D90B3-8F4B-432F-BB42-E9BE55CDAD0CQ43863073-D631F360-E513-471B-9B08-AF9F592BA70BQ44082556-DC4752AC-A2E2-48C7-B660-93EB229E07E7Q45056895-BCC9F627-BF4E-4B25-BD6F-99957E3606E6Q45105336-72EEF5E8-FD80-47DE-ABFA-6D3FF6054794Q46202171-AE46014E-6B66-4225-B35E-762DD676E68CQ46277755-BF673BC1-5D34-4741-AA4C-C5EA8BA77D5AQ46299909-7E98D009-5FD1-4FBA-AFA4-999897E16FB9Q46355851-BCFC777F-E2BA-47FC-ACF0-08C063135266Q47823874-C2CF938C-C25F-490B-9615-6F81BD2AAF71Q47869760-4EE72CFF-700E-4501-A246-425124C54276Q48188647-08503FD9-79EC-4433-B4C1-684ABB8CDD78Q48214023-AF47CE24-8706-4890-8864-91E789A6B5A5Q48238522-A37C7AEB-4346-4F04-9D91-AD07AD05FB94Q51640655-4337C39B-1397-447C-99A4-A36C02D55889Q51967939-7FED5943-FBA1-4975-994E-219DCE493FD8Q53646030-8E7C37E4-2674-4066-9F7C-3621527240F2Q54278375-532669D5-49FA-4F75-8944-BD1F4A9A14CBQ54291073-0DC12E78-A25C-4EAE-AD93-71FFB6366508Q56945472-0A034282-B155-4FDC-AE8C-E1F02D1B9E81Q57922611-DC6FB956-D4F8-4924-996F-B46CC300E679Q64951034-B83BDC13-8E07-4146-88CD-C563CC8AAD8FQ64998251-3391447A-CC9C-4F90-99FD-958E9DCAB836Q67562004-D81245A0-A5E3-4E0F-9679-AD31D16D6E75Q67580488-1DB534B0-37EB-44F7-BE3A-07C8162EA907
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Gershon Golomb
@ast
Gershon Golomb
@en
Gershon Golomb
@es
Gershon Golomb
@nl
Gershon Golomb
@sl
type
label
Gershon Golomb
@ast
Gershon Golomb
@en
Gershon Golomb
@es
Gershon Golomb
@nl
Gershon Golomb
@sl
prefLabel
Gershon Golomb
@ast
Gershon Golomb
@en
Gershon Golomb
@es
Gershon Golomb
@nl
Gershon Golomb
@sl
P1053
C-6342-2012
P106
P1153
7005302858
P31
P3829
P3835
gershon-golomb
P496
0000-0002-7369-9831